Over the past decade, Explicyte has partnered with pharmaceutical companies and Comprehensive Cancer Centers in the context of translational biomarker programs and early-phase clinical trials.
These collaborations led to the publication of 30+ peer-reviewed papers in top-tier journals, characterizing the response/resistance to cancer immunotherapies and identifying novel predictive biomarkers of anti-tumor immune response.
Explicyte is headquartered at the Institut Bergonié Comprehensive Cancer Center in Bordeaux, France
End-to-end traceability: ISO-certified quality management system
Contained variability: standardized sample QC & processing
Secured samples & data: safe storage, sample return procedures, secured data transfer (DTA)
Design & Development of tissue biomarker assays (single- and multiplex IHC/IHF panels)
Analysis of tissue biomarkers to support patient selection in clinical trials.
TLS detection & scoring: first validated biomarker panel under ISO certifications
Our technology offer allows us to process both tumor biopsies (Fresh/FFPE) and liquid clinical samples for the discovery of predictive biomarkers or for the monitoring early signals of pharmacodynamic activity in the context of clinical trials.
Building on our digital pathology platform, we set up an ISO-certified histopathology workflow to support clinical trials:
Assay design: Marker selection, positive, & negative control tissues
Panel development: Antibody & staining sequence validation for multiplex panel
Method validation: Sensitivity, specificity, reproducibility, pathology review harmonization
Validation on clinical cohort: Evaluation of assay robustness & clinical relevance
Explicyte is certified ISO 13485:2016 & ISO 9001:2015 by Euro-Quality System (certificates 260133/1637F/1 and 260133/1637F/2). Scope: Precision Oncology – Design and development of novel tissue biomarkers – Tissue biomarker testing services to support therapeutic decision-making
Why working with Explicyte?
Paul Marteau, PharmD (preclinical study director), Imane Nafia, PhD (CSO), Loïc Cerf, MSc (COO), Alban Bessede, PhD (founder, CEO), Jean-Philippe Guégan, PhD (CTO)
